UBS Starts Genzyme (GENZ) at Buy
More News related to GENZ
- Genzyme Begins Enrollment in Post-Marketing Study to Evaluate Use of Low Dose Fabrazyme Treatment for Fabry Disease
- Safe-BioPharma Recommends DEA Use Existing Federal Infrastructure to Manage ePrescriptions for Controlled Substances
- Genzyme Recognized by Scientists as a Top Employer
- SAFE-BioPharma Announces Fast, Innovative Identity Proofing Procedure
- Genzyme Provides Details of October Myozyme (alglucosidase alfa) Advisory Panel Meeting and Additional Regulatory Updates
More News related to New Coverage
- RBC Capital Upgrades First Mercury Financial (FMR) to Outperform
- Hilliard Lyons Upgrades Delta Natural Gas (DGAS) to Buy
- Brean Murray Upgrades bebe stores (BEBE) to Buy, Saying Value Too Deep - Expectations So Low
- Stanford Upgrades Virgin Mobile USA (VM) to Hold
- Goldman Sachs Upgrades Smith & Nephew (SNN) to Neutral
UBS initiates coverage on Genzyme Corp. (Nasdaq: GENZ) with a Buy rating.
Genzyme Corporation operates as a biotechnology company worldwide. It operates through five segments: Renal, Therapeutics, Transplant, Biosurgery, and Genetics.
Related Categories
New CoverageStocks Mentioned
-6.53Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
